FDA green­lights first made-in-Chi­na PD-1 as Jun­shi, Co­herus beat BeiGene to the punch

The first Chi­nese PD-1 is com­ing to the US mar­ket, as the FDA ap­proves tori­pal­imab in re­cur­rent or metasta­t­ic na­sopha­ryn­geal car­ci­no­ma (NPC) across all lines of treat­ment.

Jun­shi Bio­sciences — which back in 2018 be­came the first drug­mak­er to win ap­proval in Chi­na for a home­grown check­point in­hibitor — was the orig­i­nal de­vel­op­er of the drug. But Co­herus Bio­Sciences paid $150 mil­lion up­front in ear­ly 2021 for US and Cana­da rights. The an­ti­body, which is mar­ket­ed as Tuoyi in Chi­na, will be brand­ed as Lo­q­torzi in the US, with its launch planned for the first quar­ter of 2024.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER